Talphera, Inc. (TLPH) 10-Year Financial Performance & Capital Metrics

TLPH • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

AboutTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.Show more

Revenue $0 -100.0%
EBITDA -$15M +9.7%
Net Income -$13M +29.3%
EPS (Diluted) -0.50 +61.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -117.65% -14.9%
ROIC -162.84% -60.4%
Debt/Equity 0.82
Interest Coverage -38.71 +69.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 81.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-90.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM44.93%

ROCE

10Y Avg-51.21%

5Y Avg-61.42%

3Y Avg-69.58%

Latest-96.92%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.26M	17.36M	8M	2.15M	2.29M	5.42M	378K	0	651K	0
Revenue Growth %	2.69%	-0.1%	-0.54%	-0.73%	0.06%	1.37%	-0.93%	-1%	-	-1%
Cost of Goods Sold+	24.26M	12.31M	10.66M	3.98M	6.81M	6.03M	3.01M	1.65M	5.55M	6.72M
COGS % of Revenue	1.26%	0.71%	1.33%	1.85%	2.97%	1.11%	7.95%	-	8.52%	-
Gross Profit+	-5M	5.04M	-2.66M	-1.82M	-4.52M	-616K	-2.63M	-1.65M	-4.89M	-6.72M
Gross Margin %	-0.26%	0.29%	-0.33%	-0.85%	-1.97%	-0.11%	-6.95%	-	-7.52%	-
Gross Profit Growth %	0.74%	2.01%	-1.53%	0.31%	-1.48%	0.86%	-3.27%	0.37%	-1.97%	-0.37%
Operating Expenses+	13.32M	37M	36.02M	33.9M	49.69M	40.35M	15.49M	18.7M	11.99M	8.53M
OpEx % of Revenue	0.69%	2.13%	4.51%	15.76%	21.71%	7.45%	40.97%	-	18.42%	-
Selling, General & Admin	14.2M	15.6M	16.61M	20.77M	45.03M	36.33M	0	17.01M	0	0
SG&A % of Revenue	0.74%	0.9%	2.08%	9.65%	19.67%	6.71%	-	-	-	-
Research & Development	22.49M	21.4M	19.41M	13.14M	4.66M	4.02M	2.44M	1.69M	5.55M	6.72M
R&D % of Revenue	1.17%	1.23%	2.43%	6.11%	2.04%	0.74%	6.44%	-	8.52%	-
Other Operating Expenses	0	0	0	0	0	0	13.05M	0	6.45M	1.82M
Operating Income+	-19.2M	-31.96M	-38.68M	-35.73M	-54.2M	-40.96M	-18.12M	-20.35M	-16.89M	-15.25M
Operating Margin %	-1%	-1.84%	-4.84%	-16.61%	-23.68%	-7.56%	-47.93%	-	-25.94%	-
Operating Income Growth %	0.49%	-0.66%	-0.21%	0.08%	-0.52%	0.24%	0.56%	-0.12%	0.17%	0.1%
EBITDA+	-17.21M	-29.91M	-36.94M	-35.15M	-52.54M	-39.11M	-16.14M	-18.7M	-16.79M	-15.16M
EBITDA Margin %	-0.89%	-1.72%	-4.62%	-16.34%	-22.95%	-7.22%	-42.71%	-	-25.8%	-
EBITDA Growth %	0.53%	-0.74%	-0.24%	0.05%	-0.49%	0.26%	0.59%	-0.16%	0.1%	0.1%
D&A (Non-Cash Add-back)	1.98M	2.05M	1.74M	575K	1.67M	1.85M	1.97M	1.65M	96K	96K
EBIT	-18.23M	-31.04M	-38.17M	-34.59M	-50.7M	-37.07M	-18.12M	60.25M	-16.89M	-15.25M
Net Interest Income+	-3.69M	-11.23M	-13.53M	-11.42M	968K	588K	871K	386K	6.6M	-394K
Interest Income	1.72M	918K	510K	1.14M	3.5M	3.89M	3.16M	1.5M	6.74M	0
Interest Expense	5.41M	12.15M	14.04M	12.56M	2.54M	3.31M	2.29M	1.12M	134K	394K
Other Income/Expense	-4.44M	-11.23M	-13.53M	-11.42M	968K	588K	969K	79.49M	6.6M	2.25M
Pretax Income+	-23.64M	-43.19M	-52.21M	-47.15M	-53.24M	-40.38M	-17.15M	59.14M	-10.29M	-13M
Pretax Margin %	-1.23%	-2.49%	-6.53%	-21.92%	-23.26%	-7.45%	-45.36%	-	-15.8%	-
Income Tax+	760K	-34K	-701K	2K	3K	4K	5K	13K	0	0
Effective Tax Rate %	1.03%	1%	0.99%	1%	1%	1%	2.05%	0.72%	1.79%	1%
Net Income+	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-35.1M	42.52M	-18.4M	-13M
Net Margin %	-1.27%	-2.49%	-6.44%	-21.92%	-23.26%	-7.46%	-92.85%	-	-28.26%	-
Net Income Growth %	0.27%	-0.77%	-0.19%	0.08%	-0.13%	0.24%	0.13%	2.21%	-1.43%	0.29%
Net Income (Continuing)	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-17.15M	59.13M	-10.29M	-13M
Discontinued Operations	0	0	0	0	0	0	-17.95M	-11.37M	-8.11M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-10.97	-19.05	-21.97	-16.14	-13.45	-9.47	-5.86	5.72	-1.29	-0.50
EPS Growth %	0.27%	-0.74%	-0.15%	0.27%	0.17%	0.3%	0.38%	1.98%	-1.23%	0.61%
EPS (Basic)	-11.93	-19.05	-21.97	-16.14	-13.45	-9.47	-5.86	5.73	-1.29	-0.50
Diluted Shares Outstanding	2.22M	2.27M	2.34M	2.92M	3.96M	4.26M	5.99M	7.41M	14.26M	25.85M
Basic Shares Outstanding	2.05M	2.27M	2.34M	2.92M	3.96M	4.26M	5.99M	7.41M	14.26M	25.85M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	118.95M	89.05M	63.41M	107.99M	71.69M	46.83M	50.49M	24.57M	11.56M	9.42M
Cash & Short-Term Investments	113.46M	80.31M	60.47M	105.72M	66.14M	42.89M	46.63M	15.77M	9.38M	8.86M
Cash Only	107.92M	80.31M	52.9M	87.97M	14.68M	27.27M	7.66M	15.28M	5.72M	8.86M
Short-Term Investments	5.54M	0	7.57M	17.74M	51.45M	15.61M	38.97M	495K	3.66M	0
Accounts Receivable	3.29M	5.83M	1.53M	401K	432K	635K	160K	309K	0	0
Days Sales Outstanding	62.26	122.66	69.99	68.05	68.89	42.79	154.5	-	-	-
Inventory	466K	2.15M	956K	854K	3.29M	1.63M	1.11M	1.18M	0	0
Days Inventory Outstanding	7.01	63.84	32.74	78.4	176.71	98.39	134.9	261.06	-	-
Other Current Assets	0	0	0	0	0	0	0	2.31M	-20K	0
Total Non-Current Assets+	8.84M	10.94M	12.14M	12.54M	19.67M	19.46M	27.4M	22.92M	8.84M	8.82M
Property, Plant & Equipment	8.61M	10.71M	11.05M	11.48M	18.48M	18.81M	20.23M	13.86M	0	0
Fixed Asset Turnover	2.24x	1.62x	0.72x	0.19x	0.12x	0.29x	0.02x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	8.82M	8.82M	0
Long-Term Investments	0	178K	881K	529K	0	0	0	0	0	0
Other Non-Current Assets	228K	50K	207K	527K	1.19M	656K	7.17M	246K	20K	8.82M
Total Assets+	127.78M	99.99M	75.55M	120.53M	91.36M	66.3M	77.89M	47.49M	20.39M	18.24M
Asset Turnover	0.15x	0.17x	0.11x	0.02x	0.03x	0.08x	0.00x	-	0.03x	-
Asset Growth %	0.48%	-0.22%	-0.24%	0.6%	-0.24%	-0.27%	0.17%	-0.39%	-0.57%	-0.11%
Total Current Liabilities+	12.78M	10.19M	13.66M	15.93M	13.61M	17.64M	18.51M	13.77M	4.51M	2.65M
Accounts Payable	1.56M	1.56M	1.42M	2.07M	1.72M	2.74M	2.12M	1.26M	1.34M	670K
Days Payables Outstanding	23.49	46.18	48.76	190.03	92.24	165.62	257.54	278.35	87.93	36.4
Short-Term Debt	4.66M	3.68M	8.33M	9M	4.98M	8.73M	8.8M	5.36M	0	0
Deferred Revenue (Current)	0	362K	362K	315K	0	0	86K	115K	0	0
Other Current Liabilities	2.6M	2.56M	2.19M	3.61M	411K	155K	2.97M	2.8M	1.17M	723K
Current Ratio	9.31x	8.74x	4.64x	6.78x	5.27x	2.66x	2.73x	1.78x	2.56x	3.56x
Quick Ratio	9.27x	8.53x	4.57x	6.73x	5.02x	2.56x	2.67x	1.70x	2.56x	3.56x
Cash Conversion Cycle	45.79	140.33	53.96	-43.58	153.35	-24.43	31.86	-	-	-
Total Non-Current Liabilities+	81.89M	95.14M	98.4M	100.35M	119.16M	104.41M	95.28M	11.9M	1.78M	7.59M
Long-Term Debt	79.88M	90.86M	94.35M	96.67M	112.2M	13.14M	5.01M	0	0	6.53M
Capital Lease Obligations	0	0	0	0	3.64M	2.61M	3.75M	2.96M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.02M	455K	585K	537K	3.32M	88.66M	85.37M	7.91M	1.78M	1.06M
Total Liabilities	94.67M	105.33M	112.06M	116.28M	132.77M	122.05M	113.79M	25.67M	6.29M	10.24M
Total Debt+	84.53M	94.54M	102.68M	105.67M	121.79M	25.6M	18.62M	10.02M	0	6.53M
Net Debt	-23.39M	14.23M	49.78M	17.7M	107.11M	-1.68M	10.96M	-5.25M	-5.72M	-2.34M
Debt / Equity	2.55x	-	-	24.85x	-	-	-	0.46x	-	0.82x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.55x	-2.63x	-2.76x	-2.84x	-21.38x	-12.39x	-7.91x	-18.24x	-126.04x	-38.71x
Total Equity+	33.11M	-5.34M	-36.51M	4.25M	-41.42M	-55.75M	-35.89M	21.81M	14.11M	8M
Equity Growth %	-0.29%	-1.16%	-5.84%	1.12%	-10.74%	-0.35%	0.36%	1.61%	-0.35%	-0.43%
Book Value per Share	14.89	-2.36	-15.57	1.46	-10.46	-13.08	-5.99	2.95	0.99	0.31
Total Shareholders' Equity	33.11M	-5.34M	-36.51M	4.25M	-41.42M	-55.75M	-35.89M	21.81M	14.11M	8M
Common Stock	45K	45K	51K	78K	79K	98K	7K	8K	17K	17K
Retained Earnings	-203.21M	-246.36M	-297.87M	-345.02M	-398.11M	-438.49M	-473.58M	-425.83M	-444.23M	-457.23M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	3K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.95M	-29.39M	-29.77M	-29.07M	-51.18M	-38.51M	-30M	-28.33M	-17.49M	-12.68M
Operating CF Margin %	-1.04%	-1.69%	-3.72%	-13.52%	-22.36%	-7.11%	-79.37%	-	-26.87%	-
Operating CF Growth %	0.42%	-0.47%	-0.01%	0.02%	-0.76%	0.25%	0.22%	0.06%	0.38%	0.27%
Net Income	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-35.1M	47.76M	-18.4M	-13M
Depreciation & Amortization	1.98M	2.05M	1.74M	575K	1.67M	1.85M	1.97M	1.65M	311K	-121K
Stock-Based Compensation	5.01M	4.48M	4.29M	5.17M	5.06M	4.42M	4.61M	2.89M	1.73M	989K
Deferred Taxes	0	0	0	0	-11.84M	712K	810K	0	2.2M	0
Other Non-Cash Items	1.87M	22.76M	14.96M	14.74M	11.08M	-2.83M	-2.5M	-79.23M	-1.79M	-323K
Working Capital Changes	-4.42M	-2.27M	3.7M	1.87M	-3.91M	-2.29M	203K	-1.39M	-1.54M	-224K
Change in Receivables	-3.29M	-2.55M	3.6M	1.48M	-31K	-203K	475K	-149K	-189K	0
Change in Inventory	-466K	-1.69M	920K	102K	-3.39M	957K	-295K	-107K	61K	0
Change in Payables	0	-437K	309K	458K	-19K	1.02M	111K	551K	-575K	-671K
Cash from Investing+	8.2M	1.81M	-9.97M	-10.88M	-36.56M	34.14M	-26.12M	36.45M	-528K	3.78M
Capital Expenditures	-1.46M	-3.72M	-2.4M	-819K	-3.47M	-1.85M	-1.83M	-364K	-100K	0
CapEx % of Revenue	0.08%	0.21%	0.3%	0.38%	1.52%	0.34%	4.83%	-	0.15%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.66M	5.53M	-7.57M	-10.06M	-33.09M	35.99M	0	-1.69M	2.72M	0
Cash from Financing+	59.63M	-26K	12.33M	75.03M	14.45M	16.96M	41.51M	-507K	3.47M	12.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	64.17M	-26K	147K	1.22M	553K	286K	69K	16K	26K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.41M	-33.12M	-32.17M	-29.89M	-54.65M	-40.36M	-31.83M	-28.7M	-17.59M	-12.68M
FCF Margin %	-1.11%	-1.91%	-4.02%	-13.9%	-23.88%	-7.45%	-84.2%	-	-27.02%	-
FCF Growth %	0.46%	-0.55%	0.03%	0.07%	-0.83%	0.26%	0.21%	0.1%	0.39%	0.28%
FCF per Share	-9.63	-14.62	-13.72	-10.24	-13.80	-9.47	-5.31	-3.87	-1.23	-0.49
FCF Conversion (FCF/Net Income)	0.82x	0.68x	0.58x	0.62x	0.96x	0.95x	0.85x	-0.67x	0.95x	0.98x
Interest Paid	0	0	0	1.67M	0	0	0	837K	0	0
Taxes Paid	0	0	0	2K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-61.17%	-310.75%	-	-1108.61%	-	-	-	194.9%	-102.44%	-117.65%
Return on Invested Capital (ROIC)	-135.73%	-257.52%	-261.81%	-152.16%	-92.78%	-743.43%	-	-92.16%	-101.55%	-162.84%
Gross Margin	-25.93%	29.05%	-33.32%	-84.84%	-197.34%	-11.37%	-695.24%	-	-751.92%	-
Net Margin	-126.66%	-248.64%	-644.25%	-2191.96%	-2325.91%	-745.55%	-9285.45%	-	-2825.96%	-
Debt / Equity	2.55x	-	-	24.85x	-	-	-	0.46x	-	0.82x
Interest Coverage	-3.55x	-2.63x	-2.76x	-2.84x	-21.38x	-12.39x	-7.91x	-18.24x	-126.04x	-38.71x
FCF Conversion	0.82x	0.68x	0.58x	0.62x	0.96x	0.95x	0.85x	-0.67x	0.95x	0.98x
Revenue Growth	269.24%	-9.89%	-53.94%	-73.1%	6.42%	136.61%	-93.02%	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

Talphera, Inc. (TLPH) reported $0.0M in revenue for fiscal year 2024. This represents a 97% decrease from $1.1M in 2011.

Talphera, Inc. (TLPH) saw revenue decline by 100.0% over the past year.

Talphera, Inc. (TLPH) reported a net loss of $12.4M for fiscal year 2024.

Dividend & Returns

Talphera, Inc. (TLPH) has a return on equity (ROE) of -117.7%. Negative ROE indicates the company is unprofitable.

Talphera, Inc. (TLPH) had negative free cash flow of $11.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Talphera, Inc. (TLPH) 10-Year Financial Performance & Capital Metrics

TLPH • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

Revenue $0 -100.0%
EBITDA -$15M +9.7%
Net Income -$13M +29.3%
EPS (Diluted) -0.50 +61.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -117.65% -14.9%
ROIC -162.84% -60.4%
Debt/Equity 0.82
Interest Coverage -38.71 +69.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 81.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-90.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM44.93%

ROCE

10Y Avg-51.21%

5Y Avg-61.42%

3Y Avg-69.58%

Latest-96.92%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.26M	17.36M	8M	2.15M	2.29M	5.42M	378K	0	651K	0
Revenue Growth %	2.69%	-0.1%	-0.54%	-0.73%	0.06%	1.37%	-0.93%	-1%	-	-1%
Cost of Goods Sold+	24.26M	12.31M	10.66M	3.98M	6.81M	6.03M	3.01M	1.65M	5.55M	6.72M
COGS % of Revenue	1.26%	0.71%	1.33%	1.85%	2.97%	1.11%	7.95%	-	8.52%	-
Gross Profit+	-5M	5.04M	-2.66M	-1.82M	-4.52M	-616K	-2.63M	-1.65M	-4.89M	-6.72M
Gross Margin %	-0.26%	0.29%	-0.33%	-0.85%	-1.97%	-0.11%	-6.95%	-	-7.52%	-
Gross Profit Growth %	0.74%	2.01%	-1.53%	0.31%	-1.48%	0.86%	-3.27%	0.37%	-1.97%	-0.37%
Operating Expenses+	13.32M	37M	36.02M	33.9M	49.69M	40.35M	15.49M	18.7M	11.99M	8.53M
OpEx % of Revenue	0.69%	2.13%	4.51%	15.76%	21.71%	7.45%	40.97%	-	18.42%	-
Selling, General & Admin	14.2M	15.6M	16.61M	20.77M	45.03M	36.33M	0	17.01M	0	0
SG&A % of Revenue	0.74%	0.9%	2.08%	9.65%	19.67%	6.71%	-	-	-	-
Research & Development	22.49M	21.4M	19.41M	13.14M	4.66M	4.02M	2.44M	1.69M	5.55M	6.72M
R&D % of Revenue	1.17%	1.23%	2.43%	6.11%	2.04%	0.74%	6.44%	-	8.52%	-
Other Operating Expenses	0	0	0	0	0	0	13.05M	0	6.45M	1.82M
Operating Income+	-19.2M	-31.96M	-38.68M	-35.73M	-54.2M	-40.96M	-18.12M	-20.35M	-16.89M	-15.25M
Operating Margin %	-1%	-1.84%	-4.84%	-16.61%	-23.68%	-7.56%	-47.93%	-	-25.94%	-
Operating Income Growth %	0.49%	-0.66%	-0.21%	0.08%	-0.52%	0.24%	0.56%	-0.12%	0.17%	0.1%
EBITDA+	-17.21M	-29.91M	-36.94M	-35.15M	-52.54M	-39.11M	-16.14M	-18.7M	-16.79M	-15.16M
EBITDA Margin %	-0.89%	-1.72%	-4.62%	-16.34%	-22.95%	-7.22%	-42.71%	-	-25.8%	-
EBITDA Growth %	0.53%	-0.74%	-0.24%	0.05%	-0.49%	0.26%	0.59%	-0.16%	0.1%	0.1%
D&A (Non-Cash Add-back)	1.98M	2.05M	1.74M	575K	1.67M	1.85M	1.97M	1.65M	96K	96K
EBIT	-18.23M	-31.04M	-38.17M	-34.59M	-50.7M	-37.07M	-18.12M	60.25M	-16.89M	-15.25M
Net Interest Income+	-3.69M	-11.23M	-13.53M	-11.42M	968K	588K	871K	386K	6.6M	-394K
Interest Income	1.72M	918K	510K	1.14M	3.5M	3.89M	3.16M	1.5M	6.74M	0
Interest Expense	5.41M	12.15M	14.04M	12.56M	2.54M	3.31M	2.29M	1.12M	134K	394K
Other Income/Expense	-4.44M	-11.23M	-13.53M	-11.42M	968K	588K	969K	79.49M	6.6M	2.25M
Pretax Income+	-23.64M	-43.19M	-52.21M	-47.15M	-53.24M	-40.38M	-17.15M	59.14M	-10.29M	-13M
Pretax Margin %	-1.23%	-2.49%	-6.53%	-21.92%	-23.26%	-7.45%	-45.36%	-	-15.8%	-
Income Tax+	760K	-34K	-701K	2K	3K	4K	5K	13K	0	0
Effective Tax Rate %	1.03%	1%	0.99%	1%	1%	1%	2.05%	0.72%	1.79%	1%
Net Income+	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-35.1M	42.52M	-18.4M	-13M
Net Margin %	-1.27%	-2.49%	-6.44%	-21.92%	-23.26%	-7.46%	-92.85%	-	-28.26%	-
Net Income Growth %	0.27%	-0.77%	-0.19%	0.08%	-0.13%	0.24%	0.13%	2.21%	-1.43%	0.29%
Net Income (Continuing)	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-17.15M	59.13M	-10.29M	-13M
Discontinued Operations	0	0	0	0	0	0	-17.95M	-11.37M	-8.11M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-10.97	-19.05	-21.97	-16.14	-13.45	-9.47	-5.86	5.72	-1.29	-0.50
EPS Growth %	0.27%	-0.74%	-0.15%	0.27%	0.17%	0.3%	0.38%	1.98%	-1.23%	0.61%
EPS (Basic)	-11.93	-19.05	-21.97	-16.14	-13.45	-9.47	-5.86	5.73	-1.29	-0.50
Diluted Shares Outstanding	2.22M	2.27M	2.34M	2.92M	3.96M	4.26M	5.99M	7.41M	14.26M	25.85M
Basic Shares Outstanding	2.05M	2.27M	2.34M	2.92M	3.96M	4.26M	5.99M	7.41M	14.26M	25.85M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	118.95M	89.05M	63.41M	107.99M	71.69M	46.83M	50.49M	24.57M	11.56M	9.42M
Cash & Short-Term Investments	113.46M	80.31M	60.47M	105.72M	66.14M	42.89M	46.63M	15.77M	9.38M	8.86M
Cash Only	107.92M	80.31M	52.9M	87.97M	14.68M	27.27M	7.66M	15.28M	5.72M	8.86M
Short-Term Investments	5.54M	0	7.57M	17.74M	51.45M	15.61M	38.97M	495K	3.66M	0
Accounts Receivable	3.29M	5.83M	1.53M	401K	432K	635K	160K	309K	0	0
Days Sales Outstanding	62.26	122.66	69.99	68.05	68.89	42.79	154.5	-	-	-
Inventory	466K	2.15M	956K	854K	3.29M	1.63M	1.11M	1.18M	0	0
Days Inventory Outstanding	7.01	63.84	32.74	78.4	176.71	98.39	134.9	261.06	-	-
Other Current Assets	0	0	0	0	0	0	0	2.31M	-20K	0
Total Non-Current Assets+	8.84M	10.94M	12.14M	12.54M	19.67M	19.46M	27.4M	22.92M	8.84M	8.82M
Property, Plant & Equipment	8.61M	10.71M	11.05M	11.48M	18.48M	18.81M	20.23M	13.86M	0	0
Fixed Asset Turnover	2.24x	1.62x	0.72x	0.19x	0.12x	0.29x	0.02x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	8.82M	8.82M	0
Long-Term Investments	0	178K	881K	529K	0	0	0	0	0	0
Other Non-Current Assets	228K	50K	207K	527K	1.19M	656K	7.17M	246K	20K	8.82M
Total Assets+	127.78M	99.99M	75.55M	120.53M	91.36M	66.3M	77.89M	47.49M	20.39M	18.24M
Asset Turnover	0.15x	0.17x	0.11x	0.02x	0.03x	0.08x	0.00x	-	0.03x	-
Asset Growth %	0.48%	-0.22%	-0.24%	0.6%	-0.24%	-0.27%	0.17%	-0.39%	-0.57%	-0.11%
Total Current Liabilities+	12.78M	10.19M	13.66M	15.93M	13.61M	17.64M	18.51M	13.77M	4.51M	2.65M
Accounts Payable	1.56M	1.56M	1.42M	2.07M	1.72M	2.74M	2.12M	1.26M	1.34M	670K
Days Payables Outstanding	23.49	46.18	48.76	190.03	92.24	165.62	257.54	278.35	87.93	36.4
Short-Term Debt	4.66M	3.68M	8.33M	9M	4.98M	8.73M	8.8M	5.36M	0	0
Deferred Revenue (Current)	0	362K	362K	315K	0	0	86K	115K	0	0
Other Current Liabilities	2.6M	2.56M	2.19M	3.61M	411K	155K	2.97M	2.8M	1.17M	723K
Current Ratio	9.31x	8.74x	4.64x	6.78x	5.27x	2.66x	2.73x	1.78x	2.56x	3.56x
Quick Ratio	9.27x	8.53x	4.57x	6.73x	5.02x	2.56x	2.67x	1.70x	2.56x	3.56x
Cash Conversion Cycle	45.79	140.33	53.96	-43.58	153.35	-24.43	31.86	-	-	-
Total Non-Current Liabilities+	81.89M	95.14M	98.4M	100.35M	119.16M	104.41M	95.28M	11.9M	1.78M	7.59M
Long-Term Debt	79.88M	90.86M	94.35M	96.67M	112.2M	13.14M	5.01M	0	0	6.53M
Capital Lease Obligations	0	0	0	0	3.64M	2.61M	3.75M	2.96M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.02M	455K	585K	537K	3.32M	88.66M	85.37M	7.91M	1.78M	1.06M
Total Liabilities	94.67M	105.33M	112.06M	116.28M	132.77M	122.05M	113.79M	25.67M	6.29M	10.24M
Total Debt+	84.53M	94.54M	102.68M	105.67M	121.79M	25.6M	18.62M	10.02M	0	6.53M
Net Debt	-23.39M	14.23M	49.78M	17.7M	107.11M	-1.68M	10.96M	-5.25M	-5.72M	-2.34M
Debt / Equity	2.55x	-	-	24.85x	-	-	-	0.46x	-	0.82x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.55x	-2.63x	-2.76x	-2.84x	-21.38x	-12.39x	-7.91x	-18.24x	-126.04x	-38.71x
Total Equity+	33.11M	-5.34M	-36.51M	4.25M	-41.42M	-55.75M	-35.89M	21.81M	14.11M	8M
Equity Growth %	-0.29%	-1.16%	-5.84%	1.12%	-10.74%	-0.35%	0.36%	1.61%	-0.35%	-0.43%
Book Value per Share	14.89	-2.36	-15.57	1.46	-10.46	-13.08	-5.99	2.95	0.99	0.31
Total Shareholders' Equity	33.11M	-5.34M	-36.51M	4.25M	-41.42M	-55.75M	-35.89M	21.81M	14.11M	8M
Common Stock	45K	45K	51K	78K	79K	98K	7K	8K	17K	17K
Retained Earnings	-203.21M	-246.36M	-297.87M	-345.02M	-398.11M	-438.49M	-473.58M	-425.83M	-444.23M	-457.23M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	3K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.95M	-29.39M	-29.77M	-29.07M	-51.18M	-38.51M	-30M	-28.33M	-17.49M	-12.68M
Operating CF Margin %	-1.04%	-1.69%	-3.72%	-13.52%	-22.36%	-7.11%	-79.37%	-	-26.87%	-
Operating CF Growth %	0.42%	-0.47%	-0.01%	0.02%	-0.76%	0.25%	0.22%	0.06%	0.38%	0.27%
Net Income	-24.4M	-43.16M	-51.51M	-47.15M	-53.24M	-40.38M	-35.1M	47.76M	-18.4M	-13M
Depreciation & Amortization	1.98M	2.05M	1.74M	575K	1.67M	1.85M	1.97M	1.65M	311K	-121K
Stock-Based Compensation	5.01M	4.48M	4.29M	5.17M	5.06M	4.42M	4.61M	2.89M	1.73M	989K
Deferred Taxes	0	0	0	0	-11.84M	712K	810K	0	2.2M	0
Other Non-Cash Items	1.87M	22.76M	14.96M	14.74M	11.08M	-2.83M	-2.5M	-79.23M	-1.79M	-323K
Working Capital Changes	-4.42M	-2.27M	3.7M	1.87M	-3.91M	-2.29M	203K	-1.39M	-1.54M	-224K
Change in Receivables	-3.29M	-2.55M	3.6M	1.48M	-31K	-203K	475K	-149K	-189K	0
Change in Inventory	-466K	-1.69M	920K	102K	-3.39M	957K	-295K	-107K	61K	0
Change in Payables	0	-437K	309K	458K	-19K	1.02M	111K	551K	-575K	-671K
Cash from Investing+	8.2M	1.81M	-9.97M	-10.88M	-36.56M	34.14M	-26.12M	36.45M	-528K	3.78M
Capital Expenditures	-1.46M	-3.72M	-2.4M	-819K	-3.47M	-1.85M	-1.83M	-364K	-100K	0
CapEx % of Revenue	0.08%	0.21%	0.3%	0.38%	1.52%	0.34%	4.83%	-	0.15%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.66M	5.53M	-7.57M	-10.06M	-33.09M	35.99M	0	-1.69M	2.72M	0
Cash from Financing+	59.63M	-26K	12.33M	75.03M	14.45M	16.96M	41.51M	-507K	3.47M	12.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	64.17M	-26K	147K	1.22M	553K	286K	69K	16K	26K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.41M	-33.12M	-32.17M	-29.89M	-54.65M	-40.36M	-31.83M	-28.7M	-17.59M	-12.68M
FCF Margin %	-1.11%	-1.91%	-4.02%	-13.9%	-23.88%	-7.45%	-84.2%	-	-27.02%	-
FCF Growth %	0.46%	-0.55%	0.03%	0.07%	-0.83%	0.26%	0.21%	0.1%	0.39%	0.28%
FCF per Share	-9.63	-14.62	-13.72	-10.24	-13.80	-9.47	-5.31	-3.87	-1.23	-0.49
FCF Conversion (FCF/Net Income)	0.82x	0.68x	0.58x	0.62x	0.96x	0.95x	0.85x	-0.67x	0.95x	0.98x
Interest Paid	0	0	0	1.67M	0	0	0	837K	0	0
Taxes Paid	0	0	0	2K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-61.17%	-310.75%	-	-1108.61%	-	-	-	194.9%	-102.44%	-117.65%
Return on Invested Capital (ROIC)	-135.73%	-257.52%	-261.81%	-152.16%	-92.78%	-743.43%	-	-92.16%	-101.55%	-162.84%
Gross Margin	-25.93%	29.05%	-33.32%	-84.84%	-197.34%	-11.37%	-695.24%	-	-751.92%	-
Net Margin	-126.66%	-248.64%	-644.25%	-2191.96%	-2325.91%	-745.55%	-9285.45%	-	-2825.96%	-
Debt / Equity	2.55x	-	-	24.85x	-	-	-	0.46x	-	0.82x
Interest Coverage	-3.55x	-2.63x	-2.76x	-2.84x	-21.38x	-12.39x	-7.91x	-18.24x	-126.04x	-38.71x
FCF Conversion	0.82x	0.68x	0.58x	0.62x	0.96x	0.95x	0.85x	-0.67x	0.95x	0.98x
Revenue Growth	269.24%	-9.89%	-53.94%	-73.1%	6.42%	136.61%	-93.02%	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

Talphera, Inc. (TLPH) reported $0.0M in revenue for fiscal year 2024. This represents a 97% decrease from $1.1M in 2011.

Talphera, Inc. (TLPH) saw revenue decline by 100.0% over the past year.

Talphera, Inc. (TLPH) reported a net loss of $12.4M for fiscal year 2024.

Dividend & Returns

Talphera, Inc. (TLPH) has a return on equity (ROE) of -117.7%. Negative ROE indicates the company is unprofitable.

Talphera, Inc. (TLPH) had negative free cash flow of $11.2M in fiscal year 2024, likely due to heavy capital investments.